Treatment of CNS damage from non-disordered drug use with drhq, a novel regulator of CD74 signaling

Active Grant Awarded

Award ID
R41DA064189
Recipient
Awarding agency
Obligated
$399,889

Award facts

Assistance listing
93.279 Drug Use and Addiction Research Programs
Completion date 48% complete
Place of performance
Oregon, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse awarded Virogenomics Biodevelopment, Inc. a grant of $399,889 on May 27, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds a preclinical STTR project to evaluate DRHQ, the recipient's third-generation molecule optimized for CD74 binding, and to determine whether it can reduce or reverse neuronal and axonal damage caused by methamphetamine use. Aim 1 tests whether DRHQ decreases infarct volume and improves cognitive function following methamphetamine-associated stroke. Aim 2 examines the effect of methamphetamine alone on myelinated and unmyelinated axon function in the mouse corpus callosum.

The recipient is a woman-owned small business based in Tigard, Oregon, and the place of performance is Oregon, USA. The period of performance runs from the May 27, 2026 award date to an ultimate completion date of May 31, 2027. The source identifies no sub-recipients.

The program supports basic, clinical, translational, and implementation research on substance use, including the prevention, diagnosis, and treatment of drug use, misuse, addiction, and overdose.

Description

Abstract
Non-disordered drug use (NDDU) is a severe public health concern. Stimulants like methamphetamine cause long-term damage to regions of the brain that regulate cognitive functions, psychiatric symptoms, and promote drug-seeking behavior. Methamphetamine use increases the risk of stroke and damage to white matter (WM), both of which can impact cognitive function. We have a collection of MHC class II constructs that bind to and downregulate the expression of CD74-the primary receptor for macrophage migration inhibitory factor (MIF), a key inflammatory indicator of methamphetamine use. These constructs have a therapeutic impact in animal models of stroke and can reverse the axonal dysfunction observed in a mouse model of multiple sclerosis. These constructs also have been shown to improve cognitive function and decrease the inflammation associated with exposure to methamphetamine, suggesting a highly effective therapeutic profile. Methamphetamine has been shown to exacerbate the increased infarct volume and decreased cognitive function observed following transient middle cerebral artery occlusion in mice. The direct effects of methamphetamine use on white matter function and vulnerability to ischemia remain unexplored. The primary objective of this sttr proposal is to evaluate our third-generation molecule, drhq, which has been optimized for CD74 binding and future clinical use, by determining whether IT can reduce or even reverse neuronal and axonal damage caused by methamphetamine use. In aim 1, we will evaluate whether drhq decreases infarct volume and improves cognitive function from methamphetamine-associated stroke. In aim 2, we will examine the impact of methamphetamine alone on the function of myelinated and unmyelinated axons in the corpus callosum from mice, and then, we will determine whether any reduction in axon function and integrity can be reversed following treatment with drhq. At the end of this phase 1 feasibility study, we will have determined whether drhq has the potential to be an effective treatment for neuronal and axonal damage caused by methamphetamine use including whether IT can reduce or reverse the severity observed in methamphetamine-associated stroke. If successful, drhq may be a valuable therapeutic in treating complications from methamphetamine use. Phase 2 studies would look to expand preclinical testing and work to advance drhq into clinical testing.

Quick answers

Who received award R41DA064189?

R41DA064189 was awarded to Virogenomics Biodevelopment, Inc. by National Institute on Drug Abuse (National Institutes of Health) on May 27, 2026.

How much is award R41DA064189 worth?

$399,889 has been obligated on R41DA064189.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award